natgillin/translations-raw huggingface dataset:
asplenia, HIV infection, chronic illness, or those who have other immunocompromising conditions) placing them at higher risk for invasive disease due to Streptococcus pneumoniae. 
asplenije, HIV infekcije, kronične bolesti ili drugih imunokompromitirajućih stanja).
Use with prophylactic administration of antipyretics 
Primjena s antipireticima u profilaktičkoj primjeni
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 2 doses (0.5 ml/dose) 
SADRŽAJ PO TEŽINI, VOLUMENU ILI DOZNOJ JEDINICI LIJEKA 2 doze (0,5 ml/dozi)
At the end-of-study analysis (ATP cohort), the vaccine efficacy (first episodes) against B-CAP was 18.2% (95% CI: 4.1; 30.3), against C-CAP 22.4% (95% CI: 5.7; 36.1) and against clinically suspected CAP referred for X-ray 7.3% (95% CI: 1.6; 12.6). 
iznosila je 18,2% (95% CI: 4,1; 30,3), protiv C-CAP 22,4% (95% CI: 5,7; 36,1), a protiv klinički suspektnog CAP-a upućenog na rendgensko snimanje 7,3% (95% CI: 1,6; 12,6).
Anti-1 98.7 Anti-4 99.3 Anti-5 100 
Anti-9V 99,3 Anti-14
0.5 ml of suspension in a vial (type I glass) for 1 dose with a stopper (butyl rubber). 
0,5 ml suspenzije u bočici (staklo tip I) za 1 dozu s čepom (butil guma).
2 ml of suspension in a vial (type I glass) for 4 doses with a stopper (butyl rubber). 
2 ml suspenzije u bočici (staklo tip I) za 4 doze s čepom (butil guma).
Impact on nasopharyngeal carriage (NPC) 
Utjecaj na nazofaringealno kliconoštvo
Two-dose primary series 
Primarna imunizacija s dvije doze
In comparative clinical studies, the incidence of local and general adverse events reported within 4 days after each vaccination dose was within the same range as after vaccination with 7-valent Prevenar. 
4 dana nakon svake doze cijepljenja bila je u jednakom rasponu kao nakon cijepljenja 7-valentnim cjepivom Prevenar.
EU/1/09/508/007 - pack of 10 
EU/1/09/508/007 - pakiranje od 10
The immune response to Synflorix for each of the vaccine serotypes and serotype 19A, as well as for protein D, did not appear to be influenced by SCD. 
Čini se da anemija srpastih stanica nije utjecala na imunološki odgovor na Synflorix, tj. niti na jedan od serotipova sadržanih u cjepivu, serotip 19A kao ni na protein D.
Frequencies are reported as: Very common: (≥1/10) Common: 
Učestalost nuspojava definirana je na sljedeći način: Vrlo često:
B-1330 Rixensart Belgium 
BE-1330 Rixensart
• feeling sleepy 
• osjećaj pospanosti
Pneumococcal polysaccharide serotype 11,2 
Pneumokokni polisaharid serotipa 11,2
1 ml of suspension in a vial (type I glass) for 2 doses with a stopper (butyl rubber). 
1 ml suspenzije u bočici (staklo tip I) za 2 doze s čepom (butil guma).
The reduction in B-CAP and C-CAP was greatest in children < 36 months of age (vaccine efficacy of 20.6% (95% CI: 6.5; 32.6) and 24.2% (95% CI: 7.4; 38.0) respectively). 
< 36 mjeseci (djelotvornost cjepiva iznosila je 20,6% (95% CI: 6,5; 32,6) odnosno 24,2% (95% CI: 7,4; 38,0)).
PHARMACEUTICAL FORM AND CONTENTS Suspension for injection in multidose container (4 doses) 10 MULTIDOSE vials (4 doses per vial - 0.5 ml per dose) 100 MULTIDOSE vials (4 doses per vial - 0.5 ml per dose) 
10 VIŠEDOZNIH bočica (4 doze po bočici - 0,5 ml po dozi) 100 VIŠEDOZNIH bočica (4 doze po bočici - 0,5 ml po dozi)
A clinical study conducted in South Africa assessed the immunogenicity of Synflorix after 3-dose (610-14 weeks of age) or 2-dose (6-14 weeks of age) priming followed by a booster dose at 9-10 months of age. 
Synflorix nakon primarne imunizacije s 3 doze (u dobi od 6 - 10 - 14 tjedana) ili s 2 doze (u dobi od 6 - 14 tjedana) te doze docjepljivanja u dobi od 9 - 10 mjeseci.
Pneumococcal polysaccharide serotype 141,2 
Pneumokokni polisaharid serotipa 141,2
In the study conducted in South Africa, the booster dose given at 9-10 months of age induced marked increases in antibody GMCs and OPA GMTs for each vaccine serotype and serotype 19A in both 2dose and 3-dose priming groups indicative of immunological priming. 
9 - 10 mjeseci potaknula je značajno povećanje GMC-a protutijela i OPA GMT-a za svaki serotip sadržan u cjepivu kao i za serotip 19A i u skupini koja je primarno cijepljenja s 2 doze i u onoj cijepljenoj s 3 doze, što ukazuje na primarni imunološki odgovor.
Three-dose primary series 
Primarna imunizacija s 3 doze
Pneumococcal polysaccharide serotype 51,2 
Pneumokokni polisaharid serotipa 51,2
In clinical studies the immunogenicity of Synflorix was evaluated after a 2-dose primary vaccination series (470 subjects) according to different schedules (including 6-14 weeks, 2-4 or 3-5 months of age) and after a third (booster) dose (470 subjects) given at least 6 months after the last primary dose and from the age of 9 months onwards. 
2 doze (u 470 ispitanika) prema različitim rasporedima (uključujući primjenu u dobi od 6 - 14 tjedana, 2 - 4 mjeseca ili 3 - 5 mjeseci) kao i nakon treće doze (docjepljivanja) (u 470 ispitanika) koja se davala najmanje 6 mjeseci nakon posljednje doze primarne imunizacije i od navršenih 9 mjeseci života nadalje.
MARKETING AUTHORISATION NUMBER(S) EU/1/09/508/006 - pack of 1 
12. BROJ ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/09/508/006 - pakiranje od 1
3-dose primary schedule 
neovisno o primarnom rasporedu cijepljenja.
OPA titre ≥ 8 for each vaccine serotype was comparable or higher in the catch-up group than in the 3dose primed infants. 
Udio ispitanika s ELISA mjerenom koncentracijom protutijela ≥ 0,20 µg/ml ili OPA titrom ≥ 8 za svaki serotip iz cjepiva bio je usporediv ili viši u skupini koja se cijepila nakon naknadne provedbe nakon propuštene ili odgođene imunizacije nego u dojenčadi primarno cijepljenih s tri doze.
Serotype 6B IPD 0 
IPB uzrokovan serotipom 6B IPB uzrokovan serotipom
The antibody GMCs and OPA GMTs were lower after 2-dose for most vaccine serotypes. 
Za većinu serotipova sadržanih u cjepivu, GMC-i protutijela i OPA GMT-i bili su niži nakon rasporeda s 2 doze.
Pneumococcal polysaccharide conjugate vaccine (adsorbed) 
Cjepivo protiv pneumokoka, polisaharidno, konjugirano, adsorbirano
Pneumococcal polysaccharide serotype 41,2 
Pneumokokni polisaharid serotipa 41,2
In the nested Finnish study, a significant reduction was also observed for individual serotypes 14, 23F and, in the 3 dose primary schedule, for the cross-reactive serotype 19A. 
U ugniježđenom finskom ispitivanju primijećeno je i značajno smanjenje pojedinačnih serotipova 14 i
Syringe cap 
Klip štrcaljke
Preterm infants (born after 27 weeks and less than 37 weeks of pregnancy): Your child (from 2 months to 6 months of age) will receive 3 injections with an interval of at least one month between each dose. 
Vaše dijete (u dobi od 2 mjeseca do 6 mjeseci) će primiti 3 injekcije u razmaku od najmanje jednog mjeseca između svake doze.
2100 Gödöllö 
Homoki Nagy István utca 1. 2100 Gödöllö
In a clinical study NPC was assessed in HIV positive infants (N = 83) and HIV negative infants born from HIV positive mothers (N = 101) and compared to HIV negative infants born from HIV negative mothers (N = 100). 
(N = 83) i HIV-negativne dojenčadi koju su rodile HIV-pozitivne majke (N = 101) u usporedbi s
In a large-scale phase III, randomized, double-blind clinical trial (Clinical Otitis Media and Pneumonia Study - COMPAS) conducted in Argentina, Panama and Colombia, healthy infants aged 6 to 16 weeks received either Synflorix or hepatitis B control vaccine at 2, 4 and 6 months of age followed respectively by either Synflorix or hepatitis A control vaccine at 15 to 18 months of age. 
Synflorix ili cjepivo protiv hepatitisa B kao kontrolu u 2., 4. i 6. mjesecu života, nakon čega im je u dobi od 15 do 18 mjeseci primijenjen ili Synflorix ili cjepivo protiv hepatitisa A kao kontrola.
Rare (these may occur with up to 1 in 1,000 doses of the vaccine) 
Rijetko (mogu se pojaviti u manje od 1 na 1000 doza cjepiva)
Check with your doctor or pharmacist before this vaccine is given if: • your child has a bleeding problem or bruises easily. 
Provjerite s liječnikom ili ljekarnikom prije primjene ovog cjepiva:
The vaccine is for intramuscular use only. 
Cjepivo je namijenjeno isključivo primjeni u mišić.
50 doses (0.5 ml) 
50 napunjenih štrcaljki 50 doza (0,5 ml)
Store in the original package in order to protect from light Should be used within 6 hours after first broaching of the vial 
Mora se upotrijebiti unutar 6 sati od prvog otvaranja bočice.
Package leaflet: Information for the user Synflorix suspension for injection in multidose container (4 doses) Pneumococcal polysaccharide conjugate vaccine (adsorbed) 
Uputa o lijeku: Informacije za korisnika Synflorix suspenzija za injekciju u višedoznom spremniku (4 doze) Cjepivo protiv pneumokoka, polisaharidno, konjugirano, adsorbirano
Anaphylaxis 
- kolapsu
The effect of Synflorix on nasopharyngeal carriage was studied in 2 double-blind randomised studies using an inactive control: in the nested study of FinIP in Finland (5,023 subjects) and in COMPAS (1,700 subjects). 
FinIP u Finskoj (5023 ispitanika) te u ispitivanju COMPAS (1700 ispitanika).
CI Confidence Interval (1) First episode (2) Follow up period for a maximum of 40 months from 2 weeks after third primary dose (3) Not statistically significant by pre-defined criteria (One sided p=0.032). 
(3) nije statistički značajno prema unaprijed definiranim kriterijima (jednostrana p-vrijednost = 0,032).
Anti-6B 63.1 Anti-7F 99.3 Anti-9V 99.3 Anti-14 100 Anti-18C 99.3 Anti-19F 96.1 Anti-23F 77.6 
Anti-18C 99,3 Anti-19F 96,1 Anti-23F 77,6
Package leaflet: Information for the user Synflorix suspension for injection Pneumococcal polysaccharide conjugate vaccine (adsorbed) 
Uputa o lijeku: Informacije za korisnika Synflorix suspenzija za injekciju Cjepivo protiv pneumokoka, polisaharidno, konjugirano, adsorbirano
Efficacy of Synflorix against first episodes of likely bacterial Community Acquired Pneumonia (CAP) occurring from 2 weeks after the administration of the 3rd dose was demonstrated in the ATP cohort 
Community Acquired Pneumonia, CAP), koje su se počele javljati 2 tjedna nakon primjene 3. doze, dokazana je u međuanalizi ATP kohorte (p-vrijednost ≤ 0,002) (vođena događajima; primarni cilj).
Metabolism and nutrition disorders 
Poremećaji metabolizma i prehrane vrlo često gubitak apetita
The primary infant series consists of three doses with the first dose given at 2 months of age and with an interval of at least 1 month between doses. 
pri čemu se prva primjenjuje u dobi od 2 mjeseca, s razmakom od najmanje 1 mjeseca između pojedinih doza.
Store in the original package in order to protect from light After first use, the product may be stored in a refrigerator for a maximum of 28 days 
Nakon prve primjene, cjepivo se može čuvati u hladnjaku najduže 28 dana.
Vaccine effectiveness was 6.1% (95% CI: -2.7; 14.1) for the 3+1 schedule and 7.4% (95% CI -2.8; 16.6) for 2+1 schedule for this AOM endpoint in the infant vaccinated cohort. 
Učinkovitost cjepiva za navedenu mjeru ishoda za AOM u kohorti cijepljene dojenčadi iznosila je 6,1% (95% CI: -2,7; 14,1) za raspored 3+1 te
Pneumonia 
LIJEKA
Package leaflet: Information for the user Synflorix suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (adsorbed) 
Uputa o lijeku: Informacije za korisnika Synflorix suspenzija za injekciju u napunjenoj štrcaljki Cjepivo protiv pneumokoka, polisaharidno, konjugirano, adsorbirano
IPD Invasive Pneumococcal Disease 
IPB invazivna pneumokokna bolest UC/DC učinkovitost cjepiva (FinIP) ili djelotvornost cjepiva (COMPAS)
ГлаксоСмитКлайн ЕООД Тел. 
GlaxoSmithKine Biologicals Kft.
A different place for the injection will be used for each vaccine. 
Svako cjepivo u tom slučaju, primjenjuje se na različito ubodno mjesto.
NAME OF THE MEDICINAL PRODUCT Synflorix suspension for injection in multidose container (2 doses) Pneumococcal polysaccharide conjugate vaccine (adsorbed) 
Synflorix suspenzija za injekciju u višedoznom spremniku (2 doze) Cjepivo protiv pneumokoka, polisaharidno, konjugirano, adsorbirano
GlaxoSmithKline Biologicals s.a. Rue de l'Institut 89 
GlaxoSmithKline Biologicals S.A. 89, Rue de l'Institut BE-1330 Rixensart Belgija
For most vaccine serotypes, group comparisons did not suggest any differences in post-primary immune responses between the HIV+/+ and HIV-/- groups, or the HIV+/- and HIV-/- groups, except for a trend towards a lower percentage of subjects reaching OPA titres ≥ 8 and lower OPA GMTs in the HIV+/+ group. 
osim trenda prema nižem postotku ispitanika koji su postigli OPA titre ≥ 8 i niže OPA GMT-e u skupini HIV+/+.
It has also been demonstrated that Synflorix induces an immune response to the cross-reactive serotype 19A with 48.8% (95% CI: 42.9; 54.7) of vaccinees reaching an OPA titre ≥ 8 one month after a booster dose. 
48,8% (95% CI: 42,9; 54,7) cijepljenika koji su dostigli OPA titar > 8 jedan mjesec nakon doze docjepljivanja.
NAME OF THE MEDICINAL PRODUCT Synflorix suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (adsorbed) 
Synflorix suspenzija za injekciju u napunjenoj štrcaljki Cjepivo protiv pneumokoka, polisaharidno, konjugirano, adsorbirano
may be given from the age of 9 months onwards. 
Posljednja injekcija (docjepljivanje) se može dati od navršenih 9 mjeseci nadalje.
• headache 
• koprivnjača
NAME OF THE MEDICINAL PRODUCT Synflorix suspension for injection in multidose container (4 doses) Pneumococcal polysaccharide conjugate vaccine (adsorbed) 
Synflorix suspenzija za injekciju u višedoznom spremniku (4 doze) Cjepivo protiv pneumokoka, polisaharidno, konjugirano, adsorbirano
Immunogenicity data 
Podaci o imunogenosti
Multidose vial 2-dose vial EU/1/09/508/009 4-dose vial EU/1/09/508/012 EU/1/09/508/013 
Višedozni spremnik 2-dozna bočica EU/1/09/508/009
VE Vaccine effectiveness (FinIP) or efficacy (COMPAS) N number of subjects per group 
U analizi na kraju ispitivanja (ATP kohorta) djelotvornost cjepiva (prve epizode) protiv B-CAP
Psychiatric disorders 
Klinička ispitivanja
Similar antibody GMCs and 
GMC-e protutijela i OPA GMT-e.
Infants from 6 weeks to 6 months of age 
Dojenčad u dobi od 6 tjedana do 6 mjeseci Primarna imunizacija s tri doze
10 doses (0.5 ml) 
10 napunjenih štrcaljki 10 doza (0,5 ml)
The vaccine efficacy against the first episode of NTHi AOM was 31.1% (95% CI: -3.7; 54.2, not significant). 
31,1% (95% CI: -3,7; 54,2, nije značajno).
Skin and subcutaneous tissue disorders 
Tijelo štrcaljke Zatvarač štrcaljke
Suspension for injection 
Synflorix suspenzija za injekciju
How Synflorix is given 
Kako primjenjivati Synflorix Kako se primjenjuje cjepivo
MA (EU) number (Invented) name Strength Pharmaceutical Form 
(Izmišljeno) ime Doza Farmaceutski oblik Pot primjene Unutranje pakovanje
Further information on Azacitidine Celgene can be found on the Agency's website: www.ema.europa.eu/medicines/human/EPAR/azacitidine-celgene. 
Više informacija o lijeku Azacitidin Celgene dostupno je na internetskim stranicama Agencije:www.ema.europa.eu/medicines/human/EPAR/azacitidine-celgene
This medicine is the same as Vidaza, which is already authorised in the EU. 
Ovaj lijek isti je kao lijek Vidaza, koji je već odobren u EU-u.
The effect of Azacitidine Celgene was similar in all three diseases. 
Učinak lijeka Azacitidin Celgene bio je sličan kod svih triju bolesti.
The recommended dose of Azacitidine Celgene is 75 mg per square metre body surface area (calculated using the patient's height and weight). 
Preporučena doza lijeka Azacitidin Celgene iznosi 75 mg po kvadratnom metru tjelesne površine (izračunato prema visini i tjelesnoj težini bolesnika).
It can only be obtained with a prescription and treatment should be started and monitored under the supervision of a doctor experienced in the use of cancer medicines. 
Lijek se izdaje samo na recept, a liječenje treba započeti i nadzirati liječnik s iskustvom u primjeni lijekova za liječenje raka.
If the blood counts fall too low or if the patient develops kidney problems, the next treatment cycle should be delayed or a lower dose should be used. 
Ako vrijednosti krvne slike bolesnika budu preniske ili ako se kod bolesnika razviju problemi s bubrezima, potrebno je odgoditi sljedeći ciklus terapije ili uvesti manju dozu lijeka.
Side effects reported with Azacitidine Celgene are carefully evaluated and any necessary action taken to protect patients. 
Nuspojave prijavljene za lijek Azacitidin Celgene pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
It is given as an injection under the skin of the upper arm, thigh or abdomen (tummy) every day for one week, followed by three weeks with no treatment. 
Daje se injekcijom pod kožu nadlaktice, bedra ili abdomena (trbuha) jednom dnevno tijekom sedam dana, nakon čega slijedi stanka od tri tjedna.
What measures are being taken to ensure the safe and effective use of Azacitidine Celgene? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Azacitidin Celgene?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Azacitidine Celgene have been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Azacitidin Celgene nalaze se u sažetku opisa svojstava i u uputi o lijeku.
The company that makes Vidaza has agreed that its scientific data can be used for Azacitidine Celgene (‘informed consent'). 
Tvrtka koja proizvodi lijek Vidaza pristala je da se njezini znanstveni podatci upotrijebe za lijek Azacitidin Celgene (tzv. „informirani pristanak”).
The most common side effects of Azacitidine Celgene, which may affect more than 60% of patients with myelodysplastic syndromes, CMML or AML (20 to 30% abnormal cells), are blood reactions including thrombocytopenia (low platelet counts), neutropenia (low levels of neutrophils, a type of white blood cell) and leucopenia (low white blood cell counts), side effects affecting the stomach and gut including nausea and vomiting, and injection site reactions. 
Najčešće nuspojave lijeka Acitidine Celgene koje se mogu pojaviti u više od 60 % bolesnika s mijelodisplastičnim sindromima, KMML-om ili AML-om (20 do 30 % abnormalnih stanica) su hematološke reakcije uključujući trombocitopeniju (nizak broj trombocita), neutropenija (nizak broj neutrofila, vrste bijelih krvnih stanica) i leukopenija (nizak broj bijelih krvnih stanica), nuspojave povezane s trbuhom i crijevima uključujući mučninu i povraćanje te reakcije na mjestu primjene.
Azacitidine Celgene is available as a powder to be made up into a suspension for injection. 
Lijek Azacitidin Celgene dostupan je kao prašak od kojeg se priprema suspenzija za injekciju.
Patients should be given medicines to prevent nausea (feeling sick) and vomiting before receiving Azacitidine Celgene. 
Bolesnicima je potrebno dati lijekove za sprječavanje mučnine (slabosti) i povraćanja prije nego što prime lijek Azacitidin Celgene.
The European Medicines Agency decided that Azacitidine Celgene's benefits are greater than its risks and it can be authorised for use in the EU. 
Europska agencija za lijekove zaključila je da koristi od lijeka Azacitidin Celgene nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u EU-u.
The active substance in Azacitidine Celgene, azacitidine, belongs to the group ‘antimetabolites' and can be incorporated into the genetic material of cells (RNA and DNA) instead of their natural building-block, cytidine. 
Djelatna tvar u lijeku Azacitidin Celgene, azacitidin, ubraja se u skupinu „antimetabolita” i može se ugraditi u genetski materijal stanica (RNK i DNK) umjesto njihove prirodne temeljne sastavnice citidina.
The first study involved 358 adults with intermediate to high-risk myelodysplastic syndromes, CMML or AML who were unlikely to go on to have a stem cell transplant. 
Prvo je ispitivanje obuhvatilo 358 odraslih osoba s mijelodisplastičnim sindromima srednjeg do visokog rizika, KMML-om ili AML-om, za koje nije bilo izgledno da će se podvrgnuti transplantaciji matičnih stanica.
• AML that has developed from a myelodysplastic syndrome and the bone marrow consists of 20 to 30% abnormal cells; 
• AML-a koji se razvio iz mijelodisplastičnog sindroma, a koštana srž sadrži od 20 do 30 % abnormalnih stanica;
In the second study, which involved 488 patients with AML who could not have haematopoietic stem cell transplantation and whose bone marrow contained more than 30% abnormal cells, patients receiving Azacitidine Celgene survived for an average of 10.4 months, compared with 6.5 months in patients receiving conventional care. 
U drugom su ispitivanju, koje je obuhvaćalo 488 bolesnika s AML-om koji se nisu mogli podvrgnuti transplantaciji hematopoetskih matičnih stanica i čija je koštana srž sadržavala više od 30 % abnormalnih stanica, bolesnici koji su primili lijek Azacitidin Celgene živjeli u prosjeku 10,4 mjeseci u usporedbi s onima koji su primili konvencionalnu terapiju i živjeli 6,5 mjeseci.
What is Azacitidine Celgene and what is it used for? 
Što je Azacitidin Celgene i za što se koristi?
Azacitidine Celgene (azacitidine) 
Azacitidin Celgene (azacitidin)
As for all medicines, data on the use of Azacitidine Celgene are continuously monitored. 
Kao i za sve lijekove, podatci o primjeni lijeka Azacitidin Celgene kontinuirano se prate.
For more information about using Azacitidine Celgene, see the package leaflet or contact your doctor or pharmacist. 
Više informacija o primjeni lijeka Azacitidin Celgene pročitajte u uputi o lijeku odnosno obratite se liječniku ili ljekarniku.
Azacitidine Celgene is used when the bone marrow consists of 10 to 29% abnormal cells and the bone marrow is not producing large numbers of white blood cells; 
Azacitidin Celgene primjenjuje se kada se koštana srž sadrži 10 do 29 % abnormalnih stanica i ne proizvodi velik broj bijelih krvnih stanica;
This helps to correct the problems with the maturation and growth of young blood cells in the bone marrow that cause myelodysplastic disorders, and to kill cancerous cells in leukaemia. 
Time se rješavaju problemi sazrijevanja i rasta novih krvnih stanica u koštanoj srži koje su uzrok mijelodisplastičnih poremećaja i ubijaju kancerogene stanice pri leukemiji.
Azacitidine Celgene is used in patients with an intermediate to high risk of progressing to AML or death; 
Azacitidin Celgene primjenjuje se u bolesnika sa srednjim do visokim rizikom pogoršanja stanja do AML-a ili smrti;
In this study, patients receiving Azacitidine Celgene survived for an average of 24.5 months, compared with 15.0 months in patients receiving conventional care. 
U tom su ispitivanju bolesnici koji su primili lijek Azacitidin Celgene živjeli u prosjeku 24,5 mjeseci u usporedbi s onima koji su primili konvencionalnu terapiju i živjeli 15 mjeseci.
An overview of Azacitidine Celgene and why it is authorised in the EU 
Pregled informacija o lijeku Azacitidin Celgene i zašto je odobren u EU-u
• myelodysplastic syndromes, a group of conditions where too few blood cells are produced by the bone marrow. 
• mijelodisplastičnih sindroma, skupine bolesti kod kojih koštana srž proizvodi premalo krvnih stanica.
• chronic myelomonocytic leukaemia (CMML, a cancer affecting white blood cells called monocytes). 
• kronične mijelomonocitne leukemije (KMML-a, vrste raka koja zahvaća bijele krvne stanice naziva monociti).
Azacitidine Celgene is used for the treatment of adults with the following diseases, if they cannot have haematopoietic stem cell transplantation (when the patient receives stem cells to restore the bone marrow's ability to produce healthy blood cells): 
Lijek Azacitidin Celgene koristi se za liječenje odraslih osoba koje se ne mogu podvrgnuti transplantaciji hematopoetskih matičnih stanica (kada bolesnik prima matične stanice kako bi koštana srž ponovno mogla proizvoditi zdrave krvne stanice), a boluju od sljedećih bolesti:
Other information about Azacitidine Celgene 
Ostale informacije o lijeku Azacitidin Celgene
Why is Azacitidine Celgene authorised in the EU? 
Zašto je lijek Azacitidin Celgene odobren u EU-u?
The patients' bone marrow contained up to 30% abnormal cells. 
Koštane srži bolesnika sadržavale su do 30 % abnormalnih stanica.